Clinical Proteomic Tumor Analysis Consortium (CPTAC) Tissue Purchase IDIQ

IDIQ

Description

Deliver clinically annotated biospecimens. The tissues and data will be delivered to one of Clinical Proteomic Tumor Analysis Consortium's (CPTAC) Biospecimen Core Resource(s) (BCR) for storage, quality control, processing into molecular analytes, and other research efforts.

Overview

Ceiling

$6,500,000

Primary Sponsoring Agency

National Cancer Institute (NCI) [HHS - NIH]

Who Can Use

One Agency

Primary NAICS

325413 - In-Vitro Diagnostic Substance Manufacturing

Primary PSC

6550 - In Vitro Diagnostic Substances, Reagents, Test Kits And Sets

Primary Set Aside

Small Business Set Aside - Total (SBA)

Extent Competed

Competed Under Simplified Acquisition Procedures

Related Opportunity

Full and Open Competition Tissue Purchase Order Acquisitions for NCI's Clinical Proteomic Tumor Analysis Consortium (CPTAC) (N02CO54416-02)

Clinical Proteomic Tumor Analysis Consortium (CPTAC) Tissue Purchase IDIQ awarded by National Cancer Institute (NCI) in December 2015 accepts orders through March 2021. The IDIQ has a reported ceiling of $6,500,000, and as of today, $1,925,039 has been obligated through the vehicle. The IDIQ was awarded with a Small Business Set Aside - Total (SBA) set aside and has a primary NAICS code of 325413.

Award Hierarchy

Vehicle

Clinical Proteomic Tumor Analysis Consortium (CPTAC) Tissue Purchase IDIQ

Indefinite Delivery Vehicles

Prime Contracts

Subcontracts

Status

Period of Performance

12/30/15

Start Date

3/22/21

Ordering Period End Date

100% Complete

Task Order Obligations

$1.9M

Total Obligated

$1.9M

Current Award

$1.9M

Potential Award

100% Funded

Vehicle Award Share

Contractors with greatest percentage of obligations for Clinical Proteomic Tumor Analysis Consortium (CPTAC) Tissue Purchase IDIQ

Vehicle Award Share

Federal Award Analysis